Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senexis Ltd.

www.senexis.co.uk

Latest From Senexis Ltd.

The A-List: 2008's Trend Shaping Series A Financings

Despite a miserable economy, new company formation continues apace. In biotech, recapitalizations and structured deals featured prominently; in diagnostics, interest remains strong even if rounds in 2008 were down from last year's highs; in devices, small and regional VCs have filled the void left by brand-name investors.
BioPharmaceutical Medical Device

Molecular Origami: Start-Ups Tackle Protein Folding

Start-ups are developing novel therapeutics that work by shepherding faulty proteins into their normal conformations. The risky approach, if successful, could dramatically increase the pharmaceutical arsenal. Drug companies remain skeptical, prefering to wait for clinical validation of the existing compounds before inking big deals.
BioPharmaceutical

Recent Financings of Private Companies (03/2006)

Each month, Start-Up presents a comprehensive review of young, private life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation & reagent sectors.

Deals Shaping the Medical Industry (3/06)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Senexis Ltd.
  • Senior Management
  • Mark Treherne, PhD, CEO
    David Scopes, PhD, CSO
    David Paxton, Fin. Controller
  • Contact Info
  • Senexis Ltd.
    Phone: (44) 1223 496160
    Babraham Research Campus
    Cambridge, CB22 3AT
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register